Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Solid Tumors
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) For Phase 1 dose escalation with ORIN1001 alone: advanced solid tumors for which no effective standard of care treatments are available. 2) For Phase 1 dose escalation with ORIN1001 in combination with Abraxane®: relapsed refractory metastatic breast cancer (TNBC, or ER+ HER2-) must have progressed through at least 2 lines of therapy and for whom there are no available therapies that confer a clinical benefit. 3) For Phase 2: with relapsed refractory metastatic breast cancer. 4) Life expectancy of more than 3 months.
  

You may not be eligible for this study if the following are true:

• 1) Neutrophil count <1500 2) Prior radiotherapy and surgery within 2 weeks. 3) Prior treatment with investigational drugs within 4 weeks. 4) Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6 months prior to the first dose of study drug.